2022. First-line treatment of patients with HER2-positive metastatic gastric and gastroesophageal junction cancer. Biomolecules and Biomedicine. 22, 5 (Sep. 2022), 818–825. DOI:https://doi.org/10.17305/bjbms.2021.7069.